Metastatic breast cancer

Entinostat

Entinostat is an investigational histone deacetylase inhibitor that has received approval by the US Food and Drug Administration (FDA) as a Breakthrough Therapy for the treatment of locally recurrent or metastatic oestrogen receptor-positive breast cancer when added to exemestane, in post-menopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy.[176]Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013 Jun 10;31(17):2128-35. http://www.ncbi.nlm.nih.gov/pubmed/23650416?tool=bestpractice.com ​ Entinostat continues to be evaluated in phase 3 clinical trials.[177]ClinicalTrials.gov. Ph3 study of exemestane with or without entinostat in chinese patients with hormone receptor-positive, locally advanced or metastatic breast cancer. ClinicalTrials.gov identifier: NCT03538171. Jul 2021 [internet publication]. https://clinicaltrials.gov/ct2/show/NCT03538171 [178]​ClinicalTrials.gov. Entinostat in patients with recurrent advanced hormone receptor-positive breast cancer. ClinicalTrials.gov identifier: NCT02115282. Nov 2021 [internet publication]. https://clinicaltrials.gov/ct2/show/NCT02115282